Literature DB >> 28948495

Risk Assessment of Hepatocellular Carcinoma in Patients with Hepatitis C in China and the USA.

Neehar D Parikh1, Sherry Fu2, Huiying Rao3, Ming Yang3, Yumeng Li4, Corey Powell4, Elizabeth Wu2, Andy Lin5, Baocai Xing6, Lai Wei3, Anna S F Lok2.   

Abstract

BACKGROUND: Hepatitis C (HCV) infection is an increasingly common cause of hepatocellular carcinoma (HCC) in China. AIMS: We aimed to determine differences in demographic and behavioral profiles associated with HCC in HCV+ patients in China and the USA.
METHODS: Consecutive HCV+ patients were recruited from centers in China and the USA. Clinical data and lifestyle profiles were obtained through standardized questionnaires. Multivariable analysis was conducted to determine factors associated with HCC diagnosis within groups.
RESULTS: We included 41 HCC patients from China and 71 from the USA, and 931 non-HCC patients in China and 859 in China. Chinese patients with HCC were significantly younger, less likely to be male and to be obese than US patients with HCC (all p < 0.001). Chinese patients with HCC had a significantly lower rate of cirrhosis diagnosis (36.6 vs. 78.9%, p < 0.001); however, they also had a higher rate of hepatitis B core antibody positivity (63.4 vs. 36.8%, p = 0.007). In a multivariable analysis of the entire Chinese cohort, age > 55, male sex, the presence of diabetes, and time from maximum weight were associated with HCC, while tea consumption was associated with a decreased HCC risk (OR 0.37, 95% CI 0.16-0.88). In the US cohort, age > 55, male sex, and cirrhosis were associated with HCC on multivariable analysis.
CONCLUSIONS: With the aging Chinese population and increasing rates of diabetes, there will likely be continued increase in the incidence of HCV-related HCC in China. The protective effect of tea consumption on HCC development deserves further validation.

Entities:  

Keywords:  Diabetes; HCC; HCV; Lifestyle; Tea

Mesh:

Year:  2017        PMID: 28948495     DOI: 10.1007/s10620-017-4776-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  30 in total

1.  Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma.

Authors:  Manal M Hassan; Reham Abdel-Wahab; Ahmed Kaseb; Ahmed Shalaby; Alexandria T Phan; Hashem B El-Serag; Ernest Hawk; Jeff Morris; Kanwal Pratap Singh Raghav; Ju-Seog Lee; Jean-Nicolas Vauthey; Gehan Bortus; Harrys A Torres; Christopher I Amos; Robert A Wolff; Donghui Li
Journal:  Gastroenterology       Date:  2015-03-30       Impact factor: 22.682

2.  Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model.

Authors:  Jennifer A Flemming; Ju Dong Yang; Eric Vittinghoff; W Ray Kim; Norah A Terrault
Journal:  Cancer       Date:  2014-07-16       Impact factor: 6.860

Review 3.  A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan.

Authors:  Heather Bennett; Nathalie Waser; Karissa Johnston; Jia-Horng Kao; Young-Suk Lim; Zhong-Ping Duan; Youn-Jae Lee; Lai Wei; Chien-Jen Chen; William Sievert; Yong Yuan; Hong Li
Journal:  Hepatol Int       Date:  2015-06-13       Impact factor: 6.047

4.  Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010.

Authors:  Gonghuan Yang; Yu Wang; Yixin Zeng; George F Gao; Xiaofeng Liang; Maigeng Zhou; Xia Wan; Shicheng Yu; Yuhong Jiang; Mohsen Naghavi; Theo Vos; Haidong Wang; Alan D Lopez; Christopher J L Murray
Journal:  Lancet       Date:  2013-06-08       Impact factor: 79.321

Review 5.  Update on epidemiology of hepatitis B and C in China.

Authors:  Yan Cui; Jidong Jia
Journal:  J Gastroenterol Hepatol       Date:  2013-08       Impact factor: 4.029

6.  Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S.

Authors:  Jian-Min Yuan; Sugantha Govindarajan; Kazuko Arakawa; Mimi C Yu
Journal:  Cancer       Date:  2004-09-01       Impact factor: 6.860

7.  Sex and Ethnic Differences in the Association of Obesity With Risk of Hepatocellular Carcinoma.

Authors:  Veronica Wendy Setiawan; Unhee Lim; Loren Lipworth; Shelly C Lu; John Shepherd; Thomas Ernst; Lynne R Wilkens; Brian E Henderson; Loïc Le Marchand
Journal:  Clin Gastroenterol Hepatol       Date:  2015-09-25       Impact factor: 11.382

Review 8.  Epidemiology of non-alcoholic fatty liver disease in China.

Authors:  Jian-Gao Fan; Geoffrey C Farrell
Journal:  J Hepatol       Date:  2008-11-06       Impact factor: 25.083

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China.

Authors:  J Shi; L Zhu; S Liu; W-F Xie
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

View more
  8 in total

1.  LncRNA FLJ33360 accelerates the metastasis in hepatocellular carcinoma by targeting miRNA-140/MMP9 axis.

Authors:  Zhenhui Lu; Yingzi Yu; Xiangchun Ding; Dong Jin; Genwang Wang; Yu Zhou; Yongzhao Zhu; Li Na; Yaqin He; Qi Wang
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

2.  Dexamethasone inhibits stemness maintenance and enhances chemosensitivity of hepatocellular carcinoma stem cells by inducing deSUMOylation of HIF‑1α and Oct4.

Authors:  Zhongmin Jiang; Chunyan Zhang; Xiaozhi Liu; Xiaofang Ma; Xiyun Bian; Xiaolin Xiao; Rui Gao; Yajing Sun; Wenhan Wu; Po Zhao
Journal:  Int J Oncol       Date:  2020-07-08       Impact factor: 5.650

3.  LncRNA FTX represses the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via regulating the M1/M2 polarization of Kupffer cells.

Authors:  Huajun Wu; Zhiwei Zhong; Anji Wang; Chunhui Yuan; Ke Ning; Huanhuan Hu; Chao Wang; Xiangbao Yin
Journal:  Cancer Cell Int       Date:  2020-06-24       Impact factor: 5.722

4.  Percutaneous thermal ablation combined with transcatheter arterial chemoembolization for hepatitis C virus-related hepatocellular carcinoma: Efficacy and survival.

Authors:  Yu Sun; Honghai Zhang; Jiang Long; Yonghong Zhang; Jiasheng Zheng; Chunwang Yuan
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

5.  Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.

Authors:  Yun Lu; Xiuze Jin; Cheng-A-Xin Duan; Feng Chang
Journal:  PLoS One       Date:  2018-04-10       Impact factor: 3.240

6.  FIBCD1 overexpression predicts poor prognosis in patients with hepatocellular carcinoma.

Authors:  Yan Wang; Mengjing Sun; Jibin Liu; Ying Liu; Chunyi Jiang; Huijun Zhu; Wei Wang; Yao Wang
Journal:  Oncol Lett       Date:  2019-12-04       Impact factor: 2.967

7.  Nomogram based on albumin-bilirubin grade to predict outcome of the patients with hepatitis C virus-related hepatocellular carcinoma after microwave ablation.

Authors:  Chao An; Xin Li; Xiaoling Yu; Zhigang Cheng; Zhiyu Han; Fangyi Liu; Jie Yu; Ping Liang
Journal:  Cancer Biol Med       Date:  2019-11       Impact factor: 4.248

8.  Prognosis value of liver stiffness measurements by 2D-SWE in primary HBV-positive hepatocellular carcinoma following radiofrequency ablation.

Authors:  Xinxin Xie; Yongqiang Yu
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.